August 10, 2022
Daiichi Sankyo said on August 8 that the first patient has been dosed in a global PIII study testing patritumab deruxtecan (HER3-DXd), one of its three lead antibody-drug conjugate (ADC) assets, in certain patients with EGFR-mutated non-small cell lung cancer...read more